financetom
Business
financetom
/
Business
/
Oracle Embraces 'Run Anywhere' Strategy by Enabling Databases to Run on Cloud Platforms, UBS Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Oracle Embraces 'Run Anywhere' Strategy by Enabling Databases to Run on Cloud Platforms, UBS Says
Sep 29, 2024 2:51 PM

12:01 PM EDT, 09/25/2024 (MT Newswires) -- Oracle (ORCL) has pivoted to enable its databases to run on major cloud platforms like Microsoft's ( MSFT ) Azure, Alphabet's (GOOG, GOOGL) Google Cloud, and Amazon.com's ( AMZN ) Amazon Web Services, adopting a "run anywhere" model to meet customer demand, UBS said in a note emailed Wednesday.

"The database cloud migration process has not yet kicked-off and in our view most investors have yet to wrap their arms around the potential boost to Oracle, the impact on Microsoft ( MSFT ) and even the long-tail impact on [MongoDB ( MDB ) ]," UBS said.

Feedback on Database@Azure is largely positive, with experts calling it a "game changer" that could lead to one-third of Oracle's users migrating and increasing revenue by 25%, UBS said, adding that this transition is expected to enhance Oracle Cloud Infrastructure and support over 50% infrastructure as a service growth beyond 2025, mainly benefiting Oracle in 2026 and later.

Migrating Oracle databases to Azure could significantly boost workloads, as over 80% are still on-premises, and this shift is crucial for major cloud providers given that only 35% of IT workloads are in public clouds, while Oracle's strategy to reduce database churn may limit losses to competitors, impacting the growth of smaller rivals like MongoDB ( MDB ) if customers choose the "Big 3 cloud providers" over alternatives, the note said.

UBS reaffirmed its buy rating on Oracle with a 12-month price target of $200.

Price: 167.53, Change: +1.73, Percent Change: +1.04

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Bristol Myers beats $6.4 billion lawsuit over delayed cancer drug
Bristol Myers beats $6.4 billion lawsuit over delayed cancer drug
Oct 2, 2024
Sept 30 (Reuters) - Bristol Myers Squibb ( BMY ) won the dismissal on Monday of a $6.4 billion lawsuit claiming it cheated former Celgene shareholders by delaying federal approval for the cancer drug Breyanzi and two other drugs developed by Celgene. U.S. District Judge Jesse Furman in Manhattan said UMB Bank was never properly appointed trustee for shareholders owning...
Bristol Myers beats $6.4 billion lawsuit over delayed cancer drug
Bristol Myers beats $6.4 billion lawsuit over delayed cancer drug
Oct 2, 2024
(Reuters) - Bristol Myers Squibb won the dismissal on Monday of a $6.4 billion lawsuit claiming it cheated former Celgene shareholders by delaying federal approval for the cancer drug Breyanzi and two other drugs developed by Celgene. U.S. District Judge Jesse Furman in Manhattan said UMB Bank was never properly appointed trustee for shareholders owning contingent value rights (CVR) because...
--Street Color: Lionsgate Offering US Employees Voluntary Severance, Early Retirement Program, Deadline Reports
--Street Color: Lionsgate Offering US Employees Voluntary Severance, Early Retirement Program, Deadline Reports
Oct 2, 2024
02:40 PM EDT, 09/30/2024 (MT Newswires) -- Price: 7.14, Change: -0.15, Percent Change: -2.06 ...
Wellchange Holdings Prices IPO
Wellchange Holdings Prices IPO
Oct 2, 2024
04:45 AM EDT, 10/02/2024 (MT Newswires) -- Wellchange Holdings said late Tuesday it priced its initial public offering of 2 million shares at $4 per share. Of the 2 million shares, 1.1 million are being offered by the company, while the remaining 900,000 are being offered by a selling shareholder. The company expects to raise gross proceeds of $4.4 million...
Copyright 2023-2026 - www.financetom.com All Rights Reserved